乳腺癌新辅助化疗前后CEUS定量参数的变化

doi:10.7517/issn.1674-0475.220137

摘要/Abstract

摘要： 本研究探讨超声造影（CEUS）定量参数在乳腺癌新辅助化疗前后的变化及应用价值。选取102例乳腺癌患者，均给予新辅助化疗及CEUS检查，比较化疗有效和无效患者CEUS定量参数差异。102例患者中，新辅助化疗有效和无效患者分别为48例和54例；化疗有效患者化疗后的达峰时间、峰值强度和曲线上升斜率与化疗无效患者比较，差异有统计学意义（P<0.05）；化疗有效患者化疗前后达峰时间、峰值强度和曲线上升斜率的变化值，均明显高于无效患者（P<0.05）；化疗前后达峰时间、峰值强度和曲线上升斜率变化值预测新辅助化疗疗效的ROC曲线下面积分别为0.845、0.708和0.909（P<0.05）。CEUS定量参数变化值在乳腺癌新辅助化疗疗效方面有一定应用价值。

关键词: 乳腺癌, 新辅助化疗, 超声造影, 化疗疗效

Abstract: This study explored the changes of contrast-enhanced ultrasound (CEUS) quantitative parameters before and after neoadjuvant chemotherapy of breast cancer and its clinical application value. 102 breast cancer patients were selected, and they were all given neoadjuvant chemotherapy and CEUS examination, the CEUS quantitative parameters of patients with effective and ineffective chemotherapy were compared. Among the 102 patients, neoadjuvant chemotherapy was effective in 48 patients and ineffective in 54 patients. The peak reaching time, peak intensity and curve rising slope of patients with effective chemotherapy after chemotherapy, showing statistically significant differences with patients with ineffective chemotherapy (P<0.05). The change values of peak reaching time, peak intensity and curve rising slope before and after chemotherapy in patients with effective chemotherapy after chemotherapy were significantly higher than those of ineffective patients (P<0.05). The area under the ROC curve of change value of peak reaching time, peak intensity the curve rising slope before and after chemotherapy predicted the efficacy of neoadjuvant chemotherapy were 0.845, 0.708 and 0.909, respectively (P<0.05). The change value of CEUS quantitative parameters has a certain application value in efficacy of neoadjuvant chemotherapy of breast cancer.

Key words: breast cancer, neoadjuvant chemotherapy, contrast-enhanced ultrasound, chemotherapy curative effect

刘军, 黄磊, 石家堃, 陈彤, 陈云龙. 乳腺癌新辅助化疗前后CEUS定量参数的变化[J]. 影像科学与光化学, 2022, 40(4): 922-926.

LIU Jun, HUANG Lei, SHI Jiakun, CHEN Tong, CHEN Yunlong. Changes of CEUS Quantitative Parameters before and after Neoadjuvant Chemotherapy of Breast Cancer[J]. IMAGING SCIENCE AND PHOTOCHEMISTRY, 2022, 40(4): 922-926.

参考文献

[1] 李蔓英, 李彬, 罗佳, 等. 基于灰阶超声的影像组学模型预测乳腺癌新辅助化疗效果[J]. 中国医学影像技术, 2019,35(9):1331-1335.
[2] Jia K, Li L, Wu X J, et al. Contrast-enhanced ultrasound for evaluating the pathologic response of breast cancer to neoadjuvant chemotherapy:A meta-analysis[J]. Medicine, 2019,98(4):e14258.
[3] Peppe A, Wilson R, Pope R, et al. The use of ultrasound in the clinical re-staging of the axilla after neoadjuvant chemotherapy (NACT)[J]. The Breast, 2017,35:104-108.
[4] You C, Peng W, Zhi W X, et al. Association between background parenchymal enhancement and pathologic complete remission throughout the neoadjuvant chemotherapy in breast cancer patients[J]. Translational Oncology, 2017,10(5):786-792.
[5] 蔡丽珊, 张建兴, 宋光辉, 等. 超声造影在乳腺癌早期诊断中的临床应用[J]. 南方医科大学学报, 2013,33(12):1801-1805.
[6] Mark K M K, Varn F S, Ung M H, et al. The E2F4 prognostic signature predicts pathological response to neoadjuvant chemotherapy in breast cancer patients[J].BMC Cancer, 2017,17(1):306.
[7] Haque W, Verma V, Hatch S, et al. Response rates and pathologic complete response by breast cancer molecular subtype following neoadjuvant chemotherapy[J].Breast Cancer Research and Reatment, 2018,170(3):559-567.
[8] Nam K, Eisenbrey J R, Stanczak M, et al. Monitoring neoadjuvant chemotherapy for breast cancer by using three-dimensional subharmonic aided pressure estimation and imaging with us contrast agents:Preliminary experience[J].Radiology, 2017,285(1):53-62.
[9] Akimoto E, Kadoya T, Kajitani K, et al. Role of ¹⁸F-PET/CT in predicting prognosis of patients with breast cancer after neoadjuvant chemotherapy[J]. Clinical Breast Cancer, 2018,18(1):45-52.
[10] 沈嫱, 宋光辉, 沈建红, 等. 超声造影与乳腺癌肿瘤微血管密度测定的相关性[J]. 中国医学影像技术, 2009,25(3):441-444.
[11] 林韵, 王小燕, 韦海明, 等. 乳腺癌超声造影定量分析参数及增强模式与分子分型的关系[J]. 中国医学影像技术, 2014,30(3):406-410.
[12] 万财凤, 王琳, 刘雪松, 等. 超声造影评估乳腺癌新辅助化疗疗效的临床价值[J]. 临床超声医学杂志, 2017,19(10):652-655.
[13] 潘音桦, 黄瑜, 李杰华. 乳腺癌的超声与增强MRI应用ROC曲线对比研究[J]. 中国医学创新, 2017,14(11):37-40.
[14] Li L, Roth R, Germaine P, et al. Contrast-enhanced spectral mammography (CESM) versus breast magnetic resonance imaging (MRI):A retrospective comparison in 66 breast lesions[J]. Diagnostic & Interventional Imaging, 2017,98(2):113-123.
[15] Xue L B, Liu Y H, Zhang B, et al. Prognostic role of high neutrophil-to-lymphocyte ratio in breast cancer patients receiving neoadjuvant chemotherapy:Meta-analysis[J]. Medicine, 2019,98(1):e13842.
[16] Pérez R R, Aguirre A C R, Miguel P G T S, et al. Review of the role of the sentinel node biopsy in neoadjuvant chemotherapy in women with breast cancer and negative or positive axillary node at diagnosis[J]. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2018,37(1):63-70.
[17] Weber J J, Jochelson M S, Eaton A, et al. MRI and prediction of pathologic complete response in the breast and axilla after neoadjuvant chemotherapy for breast cancer[J]. Journal of the American College of Surgeons, 2017,225(6):740-746.
[18] Cochran J M, Busch D R, Leproux A, et al. Tissue oxygen saturation predicts response to breast cancer neoadjuvant chemotherapy within 10 days of treatment[J]. Journal of Biomedical Optics, 2018,24(2):1-11.
[19] McAndrew N, DeMichele A. Neoadjuvant chemotherapy considerations in triple-negative breast cancer[J]. Journal of Targeted Therapies in Cancer, 2018,7(1):52-69.
[20] Sakata E, Endo Y, Miyahira A, et al. Brain metastasis of triple negative breast cancer after pathological complete response to neoadjuvant chemotherapy-A case report[J]. Gan to Kagaku Ryoho Cancer & Chemotherapy, 2018,45(1):184-186.